Wednesday January 10, 2018 0 comments
GOLDEN -- PharmaJet, maker of innovative, needle-free injection technology, today announced a recently published study in The Lancet demonstrated that delivery of a Zika virus vaccine with the PharmaJet Stratis® Needle-free Jet injector produced a significantly higher immune response, as compared with administration via needle and syringe.
Multiple studies have shown that needle-free injectors augment DNA vaccine response, possibly by increased dispersion of injectate or through tissue disruption that increases immunogenicity.
The GMT after split-dose needle-free delivery of VRC5283 was six times higher than single-dose delivery via needle and syringe, according to PharmaJet.
Over 700,000 cases of Zika virus infection have been reported in the Americas since 2015. The emergence of Zika virus has challenged the scientific community to address a relatively uncharacterized pathogen posing a substantial threat to international public health.
The two DNA vaccines assessed in this study were safe and well tolerated, and both were immunogenic, PharmaJet said. However, the greatest effects were seen with VRC5283 given in split doses via needle-free injection in the VRC 320 trial.
One hundred percent of participants who received the vaccine by needle-free injection in split doses had detectable antibody responses, produced neutralizing antibodies, and had the highest T-cell responses, the company said.
"We are pleased that the PharmaJet device boosted immunogenicity in this Zika virus vaccine clinical trial and we look forward to participating in the next stage of development," said Ron Lowy, PharmaJet chair and CEO.